A
2.98
0.05 (1.71%)
| Previous Close | 2.93 |
| Open | 2.93 |
| Volume | 458,273 |
| Avg. Volume (3M) | 354,771 |
| Market Cap | 288,135,008 |
| Price / Sales | 3.79 |
| 52 Weeks Range |
| Operating Margin (TTM) | -166.81% |
| Diluted EPS (TTM) | -2.54 |
| Quarterly Revenue Growth (YOY) | -9.70% |
| Current Ratio (MRQ) | 6.17 |
| Operating Cash Flow (TTM) | -145.25 M |
| Levered Free Cash Flow (TTM) | -99.86 M |
| Return on Assets (TTM) | -19.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ADC Therapeutics SA | Bearish | Bullish |
AIStockmoo Score
-1.5
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.5 |
| Average | -1.50 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 21.03% |
| % Held by Institutions | 59.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Prosight Management, Lp | 30 Jun 2024 | 9,570,000 |
| Silverarc Capital Management, Llc | 30 Jun 2024 | 1,768,770 |
| Artal Group S.A. | 30 Jun 2024 | 1,018,461 |
| Vantage Consulting Group Inc | 30 Jun 2024 | 850,737 |
| 52 Weeks Range | ||
| Median | 6.00 (101.34%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stephens & Co. | 08 Nov 2024 | 6.00 (101.34%) | Buy | 2.93 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Dec 2024 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 07 Nov 2024 | Announcement | ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update |
| 05 Nov 2024 | Announcement | ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting |
| 04 Nov 2024 | Announcement | ADC Therapeutics to Present at November Investor Conferences |
| 01 Nov 2024 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 31 Oct 2024 | Announcement | ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 |
| 01 Oct 2024 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 01 Oct 2024 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |